EBA
AMPH icon

Eagle Bay Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Eagle Bay Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-82
Closed -$3.04K – 159
2024
Q4 		$3.04K Sell
82
-12
-13% -$549 ﹤0.01% 791
2024
Q3 		$4.56K Sell
94
-11
-10% -$483 ﹤0.01% 1038
2024
Q2 		$4.2K Hold
105
– – ﹤0.01% 754
2024
Q1 		$4.61K Buy
+105
New +$5.42K ﹤0.01% 750

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eagle Bay Advisors's AMPH Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2025, closing a stake of 82 shares — an estimated $3.04K sold.

Eagle Bay Advisors first reported a position in AMPH in Q1 2024 and held it in 4 quarters. The position peaked at $4.61K in Q1 2024. 241 funds tracked by Wall St. Rank hold AMPH as of Q1 2025.

  • Eagle Bay Advisors reported no remaining Amphastar Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Eagle Bay Advisors sold 82 Amphastar Pharmaceuticals shares in Q1 2025, an estimated $3.04K.
  • Eagle Bay Advisors first reported a position in Amphastar Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Eagle Bay Advisors's Amphastar Pharmaceuticals position peaked at $4.61K in Q1 2024.
  • 241 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.